EUVIMEDEUVIMED entdecken
Crossref

The WHO system versus the Papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology for risk stratification—which is better?

Reetu Kundu iD, Arpitha Kollabathula, Nalini Gupta iD, Manish Rohilla iD, Surinder Singh Rana, Ritambhra Nada, Naveen Kalra, Rajender Kumar Basher, Parikshaa Gupta iD, Pranab Dey iD, Rajesh Gupta, Usha Dutta und 1 weitere

Diagnostic Cytopathology · 2024

DOI: 10.1002/dc.25258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2024. Verfasst von Reetu Kundu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cytology and Gynecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, the World Health Organization (WHO) has proposed a reporting system for pancreaticobiliary cytopathology. We applied this classification for pancreatic lesion samples by fine needle aspiration (FNA) and compared the results to the previous classification of the Papanicolaou Society of Cytopathology (PSC) system for risk stratification.

Methods

The computerized database was searched for all pancreatic endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) and transabdominal ultrasound‐guided FNA (TUS‐FNA) samples from 2016 to 2020 and cases were reassigned as per the PSC and the WHO diagnostic categories. Cases with follow‐up, clinicoradiological, and/or histopathology were included in the study. The risk of malignancy (ROM) was calculated across all diagnostic categories based on clinical data, imaging data, and histopathology wherever available.

Results

There were a total of 625 pancreatic FNA. In 230 cases, follow‐up information was available which included 116 EUS and 114 TUS‐FNA samples. The ROM for PSC categories I–VI was 40%, 19.7%, 28.6%, 57.1%, 94.7%, and 97.9% and for the WHO categories (I–VII), it was 60%, 21.3%, and 35.7%, not representative, not applicable, 94.7% and 94.9%. The overall sensitivity and specificity of PSC was 68.2% and 96.2% when categories V and VI were taken as positive and 78.9% and 93.3% for WHO when categories VI and VII were taken as positive.

Conclusions

Pancreatic FNA samples reported as per the WHO system showed better sensitivity as compared to the PSC system resulting in better risk stratification and consequently better patient management. The overall high specificity and moderate sensitivity reaffirm the utility of FNA in pancreatic lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsHumansPancreasEndoscopic Ultrasound-Guided Fine Needle AspirationPancreatectomyRisk Assessment

Stichwörter der Autor:innen

Papanicolaou society of cytopathologyWorld Health Organizationendoscopic ultrasoundfine-needle aspiration cytologyrisk of malignancytransabdominal ultrasound

Autor:innen und Institutionen

  • Department of Cytology and Gynecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Surgical Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Reetu Kundu, Nalini Gupta, Manish Rohilla, Parikshaa Gupta, Pranab Dey, Radhika Srinivasan

Zitieren

APA

Kundu, R., Kollabathula, A., Gupta, N., Rohilla, M., Rana, S. S., Nada, R., Kalra, N., Basher, R. K., Gupta, P., Dey, P., Gupta, R., Dutta, U., & Srinivasan, R. (2024). The WHO system versus the Papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology for risk stratification—which is better?. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25258

Vancouver

Kundu R, Kollabathula A, Gupta N, Rohilla M, Rana SS, Nada R, et al. The WHO system versus the Papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology for risk stratification—which is better?. Diagnostic Cytopathology. 2024. doi:10.1002/dc.25258

BibTeX
@article{Kundu2024,
  author = {Kundu, Reetu and Kollabathula, Arpitha and Gupta, Nalini and Rohilla, Manish and Rana, Surinder Singh and Nada, Ritambhra and Kalra, Naveen and Basher, Rajender Kumar and Gupta, Parikshaa and Dey, Pranab and Gupta, Rajesh and Dutta, Usha and Srinivasan, Radhika},
  title = {The WHO system versus the Papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology for risk stratification—which is better?},
  journal = {Diagnostic Cytopathology},
  year = {2024},
  doi = {10.1002/dc.25258}
}
Kostenlos starten →